semaglutide prediabetes progression to diabetes trial 2.4 mg weekly vs 1 mg and placebo in #obesity with T2 #diabetes Better weight loss, better reduction in waist circumference and slightly better HbA1c lowering (sugars) with fewer other sugar-lowering Semaglutide as a GLP-1 Agonist:

Leveraging 45+ years of cutting-edge science and human genetics, we are currently studying maridebart cafraglutide, or MariTide for short (formerly AMG 133), for monthly or even less frequent dosing in obesity, atherosclerotic cardiovascular disease, heart failure, obstructive sleep apnea and type 2 diabetes

2 Movement and hypothyroidism Exercise can help counteract several of the symptoms hypothyroidism causes, including fatigue, weight gain, low mood, and muscle weakness

6 Importantly, these are life-saving therapies, independent of any impact they may have on the eye

doi: 10.1097/00005373-199807000-00025

6/ How does Qsymia compare to GLP-1 medications